Metagenomi Therapeutics Operating Income 2022-2026 | MGX
Metagenomi Therapeutics operating income from 2022 to 2026. Operating income can be defined as income after operating expenses have been deducted and before interest payments and taxes have been deducted.
|
Metagenomi Therapeutics Annual Operating Income (Millions of US $) |
|
|---|---|
| 2025 | $-96 |
| 2024 | $-89 |
| 2023 | $-78 |
| 2022 | $-45 |
| 2021 | $-24 |
|
Metagenomi Therapeutics Quarterly Operating Income (Millions of US $) |
|
|---|---|
| 2026-03-31 | $-25 |
| 2025-12-31 | $-24 |
| 2025-09-30 | $-23 |
| 2025-06-30 | $-21 |
| 2025-03-31 | $-28 |
| 2024-12-31 | $-21 |
| 2024-09-30 | $-22 |
| 2024-06-30 | $-17 |
| 2024-03-31 | $-29 |
| 2023-12-31 | $-20 |
| 2023-09-30 | $-22 |
| 2023-06-30 | $-18 |
| 2023-03-31 | $-18 |
| 2022-12-31 | |
| 2021-12-31 | |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $0.052B | $0.025B |
| Metagenomi Therapeutics Inc. is an in vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients. Metagenomi Therapeutics Inc., formerly known as Metagenomi Inc., is based in EMERYVILLE, Calif. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Teva Pharmaceutical Industries (TEVA) | Israel | $35.437B | 10.97 |
| BridgeBio Pharma (BBIO) | United States | $14.460B | 0.00 |
| Dr Reddy's Laboratories (RDY) | India | $11.109B | 17.29 |
| Aspen Pharmacare (APNHY) | South Africa | $3.708B | 0.00 |
| Supernus Pharmaceuticals (SUPN) | United States | $2.918B | 22.33 |
| Bausch Health Cos (BHC) | Canada | $2.086B | 1.50 |
| Taysha Gene Therapies (TSHA) | United States | $1.290B | 0.00 |
| Amphastar Pharmaceuticals (AMPH) | United States | $0.924B | 7.28 |
| Personalis (PSNL) | United States | $0.630B | 0.00 |
| Assembly Biosciences (ASMB) | United States | $0.451B | 0.00 |
| Sol-Gel Technologies (SLGL) | Israel | $0.210B | 0.00 |
| Evoke Pharma (EVOK) | United States | $0.019B | 0.00 |
| Teligent (TLGT) | United States | $0.000B | 0.00 |